Chemistry:BP-897
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C26H31N3O2 |
| Molar mass | 417.553 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
BP-897 is a drug used in scientific research which acts as a potent selective dopamine D3 receptor partial agonist with an in vitro intrinsic activity of ~0.6 and ~70x greater affinity for D3 over D2 receptors and is suspected to have partial agonist or antagonist activity in vivo.[1] It has mainly been used in the study of treatments for cocaine addiction.[2][3][4][5][6][7][8] A study comparing BP-897 with the potent, antagonistic, and highly D3 selective SB-277,011-A found, "SB 277011-A (1–10 mg/kg) was able to block cue-induced reinstatement of nicotine-seeking, indicating that DRD3 selective antagonism may be an effective approach to prevent relapse for nicotine. In contrast, BP 897 did not block the cue-induced reinstatement of nicotine-seeking or nicotine-taking under the FR5 schedule."[9]
References
- ↑ "Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist". Nature 400 (6742): 371–375. July 1999. doi:10.1038/22560. PMID 10432116.
- ↑ "The D3R partial agonist, BP 897, attenuates the discriminative stimulus effects of cocaine and D-amphetamine and is not self-administered". Behavioural Pharmacology 12 (1): 1–11. February 2001. doi:10.1097/00008877-200102000-00001. PMID 11270507.
- ↑ "BP 897, a selective dopamine D3 receptor ligand with therapeutic potential for the treatment of cocaine-addiction". CNS Drug Reviews 9 (2): 141–158. 2003. doi:10.1111/j.1527-3458.2003.tb00246.x. PMID 12847556.
- ↑ "Effects of a dopamine D3 receptor ligand, BP 897, on acquisition and expression of food-, morphine-, and cocaine-induced conditioned place preference, and food-seeking behavior in rats". Neuropsychopharmacology 28 (11): 1903–1915. November 2003. doi:10.1038/sj.npp.1300276. PMID 12915863.
- ↑ "Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys". The Journal of Pharmacology and Experimental Therapeutics 311 (2): 770–777. November 2004. doi:10.1124/jpet.104.071142. PMID 15226382.
- ↑ "Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors". Synapse 57 (1): 17–28. July 2005. doi:10.1002/syn.20152. PMID 15858839.
- ↑ "The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats". Psychopharmacology 196 (4): 533–542. March 2008. doi:10.1007/s00213-007-0986-6. PMID 17985117.
- ↑ "18F-Labeled FAUC 346 and BP 897 derivatives as subtype-selective potential PET radioligands for the dopamine D3 receptor". ChemMedChem 3 (5): 788–793. May 2008. doi:10.1002/cmdc.200700327. PMID 18306190.
- ↑ "The selective dopamine D3 receptor antagonist SB 277011-A, but not the partial agonist BP 897, blocks cue-induced reinstatement of nicotine-seeking". The International Journal of Neuropsychopharmacology 13 (2): 181–190. March 2010. doi:10.1017/S1461145709991064. PMID 19995481.
 |  |
